Ignite Creation Date:
2024-05-06 @ 7:44 AM
Last Modification Date:
2024-10-26 @ 11:52 AM
Study NCT ID:
NCT02594865
Status:
COMPLETED
Last Update Posted:
2016-06-27
First Post:
2015-09-16
Brief Title:
The Glycaemic Effects of Glucerna in Critically Ill Patients
Sponsor:
PHJ van der Voort
Organization:
Onze Lieve Vrouwe Gasthuis
Study Overview
Official Title:
Glucerna in Critically Ill Patients GluCip Trial Investigating the Glycaemic Effects of a Reduced-carbohydrate Modified-fat Fiber-containing Enteral Formula Glucerna in Critically Ill Patients
Status:
COMPLETED
Status Verified Date:
2016-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GluCip
Brief Summary:
To investigate whether the administration of Glucerna achieves less glycaemic variability defined as the mean absolute glucose MAG change and better glycaemic control compared to a standard high-carbohydrate enteral formula Continuous glucose monitoring technology will be used to evaluate glycaemic variability and glycaemic control
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None